Abstract:Background: Metabolic syndrome (MetS) is a chronic disorder featuring overweight/obesity, high blood pressure, and dysfunction of lipid and carbohydrate metabolism. Microbiome-modulating probiotics, prebiotics, synbiotics and fecal microbiota transplant (FMT) are promising adjunct therapies for improving parameters of glucose homeostasis and insulinemia. Methods: We conducted a comprehensive systematic review, meta-analyses, and meta-regressions to investigate the effect of the abovementioned microbiome therapies on various biomarkers after screening clinical trials published through April 2023. We pooled data using random effects meta-analyses, reporting them as mean differences (MDs) with 95 % confidence intervals (CIs), and conducting univariate linear model meta-regressions. Results: Data from 21 trial comparisons across 19 studies (n = 911) revealed that, compared to placebo/control, microbiome-modulating therapies were associated with statistically significant changes in fasting plasma glucose (MD: 4.03 mg/dL [95%CI: 6.93; -1.13]; p effect = 0.006, I2 = 89.8 %), and fasting insulin (MD: 2.56 μU/mL [95%CI: 4.28; -0.84]; p effect = 0.004, I2 = 87.9 %), but not insulin resistance or sensitivity indices and HbA1c. Age, baseline BMI, baseline biomarker value, pro/synbiotic dosage, trial duration, nutraceutical type, and WHO region were factors affecting the efficacy of these interventions at producing changes in biomarkers, signaling the potential role of personalized precision medicine adjunct therapy for deranged glucose homeostasis in patients with MetS. Nevertheless, presence of heterogeneity calls for further investigation before their clinical application. Conclusions: Probiotics, prebiotics, synbiotics and FMT supplementation improved fasting glucose and insulin in patients with MetS. Further large-scale and high-quality trials are required before potential clinical applications.

Food Additives' Impact on Gut Microbiota and Metabolic Syndrome: A Systematic Review

Gut microbiota-derived metabolites: implications for metabolic syndrome and therapeutic interventions

Gut Microbiota Disorders and Metabolic Syndrome: Tales of a Crosstalk Process

Food Emulsifiers and Metabolic Syndrome: The Role of the Gut Microbiota

Exploring the Gut Microbiota: Key Insights into Its Role in Obesity, Metabolic Syndrome, and Type 2 Diabetes

Harnessing the Power of the Gut Microbiome: A Review of Supplementation Therapies for Metabolic Syndrome

You Are What You Eat-The Relationship between Diet, Microbiota, and Metabolic Disorders-A Review

Dietary Strategies for Management of Metabolic Syndrome: Role of Gut Microbiota Metabolites

Dietary Polyphenols to Combat the Metabolic Diseases Via Altering Gut Microbiota

The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trials

The Impact of Food Additives on the Abundance and Composition of Gut Microbiota

Gut Microbiota and Metabolic Syndrome: Relationships and Opportunities for New Therapeutic Strategies

Food Additives And Microbiota

Advances in Gut Microbiota-Targeted Therapeutics for Metabolic Syndrome

Impact of Food Additives on Gut Homeostasis

The gut microbial community in metabolic syndrome patients is modified by diet

A Metagenome-Wide Association Study of the Gut Microbiome and Metabolic Syndrome

The role of gut microbiota in the development of metabolic syndrome

Gut Microbiota-Derived Metabolites in the Development of Diseases

Food additives, contaminants and other minor components: effects on human gut microbiota—a review

Vitamin D, Gut Microbiota, and Cardiometabolic Diseases-A Possible Three-Way Axis